First Trust Advisors LP Buys 251,241 Shares of Genmab A/S (NASDAQ:GMAB)

First Trust Advisors LP lifted its position in shares of Genmab A/S (NASDAQ:GMAB) by 18.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,644,288 shares of the company’s stock after buying an additional 251,241 shares during the period. First Trust Advisors LP owned about 0.25% of Genmab A/S worth $34,316,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in GMAB. EverSource Wealth Advisors LLC lifted its stake in shares of Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after acquiring an additional 939 shares during the last quarter. Lindbrook Capital LLC boosted its position in Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after acquiring an additional 950 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after purchasing an additional 1,051 shares in the last quarter. Barclays PLC grew its position in shares of Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company’s stock worth $52,000 after buying an additional 2,285 shares during the period. Finally, Cromwell Holdings LLC grew its holdings in Genmab A/S by 656.8% in the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after purchasing an additional 2,496 shares during the period. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Price Performance

NASDAQ:GMAB opened at $20.54 on Friday. The stock’s 50 day simple moving average is $20.50 and its two-hundred day simple moving average is $21.08. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $30.41. The company has a market cap of $13.59 billion, a price-to-earnings ratio of 11.80, a PEG ratio of 2.65 and a beta of 1.07.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, analysts anticipate that Genmab A/S will post 1.45 EPS for the current year.

Analyst Ratings Changes

GMAB has been the subject of several analyst reports. Leerink Partnrs upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research note on Thursday, February 13th. Sanford C. Bernstein cut shares of Genmab A/S from a “market perform” rating to an “underperform” rating in a research note on Tuesday, April 1st. Truist Financial lowered their target price on Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th. Finally, William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Genmab A/S has an average rating of “Moderate Buy” and an average target price of $39.17.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.